News & Updates

In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).

Among hepatitis C virus (HCV) patients with resolved hepatitis B virus (HBV) infections, levels of interleukin (IL)-1β before the initiation of direct-acting antiviral (DAA) treatment may help predict HBV reactivation, reports a recent study.

Long-term treatment with carvedilol lowers the risk of decompensation of cirrhosis and improves survival in compensated patients with clinically significant portal hypertension (CSPH), reports a study.

Fatty liver disease does not seem to contribute to prevalent or incident atrial fibrillation (AF), but higher liver stiffness does, particularly among individuals without steatosis, reports a recent study.

Current efforts to eradicate hepatitis B virus (HBV), including vaccination, screening, and treatment strategies, do not seem enough to achieve the elimination goals set by the World Health Organization (WHO), suggests a recent study.

Hepatitis B surface antigen (HBsAg) seroclearance appears to reduce the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) late recurrence among patients who underwent curative liver resection, results of a Korea study have shown.

An intensive weight-loss intervention has failed to substantially improve the treatment outcomes among obese patients with nonalcoholic fatty liver disease (NAFLD), reports a recent study.

Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.